Accepted for Publication: August 26, 2022.
Published: October 12, 2022. doi:10.1001/jamanetworkopen.2022.36288
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Hohl CM et al. JAMA Network Open.
Corresponding Author: Corinne M. Hohl, MD, MHSc, Department of Emergency Medicine, Faculty of Medicine, University of British Columbia, 2775 Laurel St, Vancouver, BC V5Z 1M9, Canada (email@example.com).
Author Contributions: Drs Hohl and Rosychuk had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Hohl, Vaillancourt, Grant, Morrison, Rosychuk.
Acquisition, analysis, or interpretation of data: Hau, Vaillancourt, Brooks, Morrison, Perry, Rosychuk.
Drafting of the manuscript: Hohl, Hau, Rosychuk.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Hau, Vaillancourt, Rosychuk.
Obtained funding: Hohl, Brooks, Morrison, Rosychuk.
Administrative, technical, or material support: Hohl, Grant, Morrison, Perry, Rosychuk.
Conflict of Interest Disclosures: Dr Hohl reported receiving grants from the Canadian Institutes of Health Research, Genome BC, Health Research BC, the Canadian Immunity Task Force/Public Health Agency of Canada, Ontario Ministry of Colleges and Universities, the Saskatchewan Health Research Foundation, and Fondation du CHU de Québec during the conduct of the study. Dr Brooks reported receiving grants from the Canadian Institutes of Health Research, Ontario Ministry of Colleges and Universities, the Saskatchewan Health Research Foundation, Genome BC, Fondation du CHU de Québec, COVID-19 Immunity Task Force, BC Academic Health Science Network, and BioTalent Canada during the conduct of the study. Dr Perry reported receiving the Heart and Stroke Foundation Canada Mid-Career Salary Award outside the submitted work. No other disclosures were reported.
Funding/Support: The network is funded by the Canadian Institutes of Health Research (447679, 464947, and 466880), Ontario Ministry of Colleges and Universities (C-655-2129), Saskatchewan Health Research Foundation (5357), Genome BC (COV024 and VAC007), Fondation du CHU de Québec (Octroi No. 4007), and Sero-Surveillance and Research (COVID-19 Immunity Task Force Initiative), which provided peer-reviewed funding; the BC Academic Health Science Network and BioTalent Canada provided non–peer-reviewed funding.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: The Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) investigators for the Network of Canadian Emergency Researchers and the Canadian Critical Care Trials Group are listed in Supplement 2.
Additional Contributions: We gratefully acknowledge the University of British Columbia clinical coordinating centre staff; the University of British Columbia legal, ethics, privacy, and contracts staff; and the research staff at each of the participating institutions in the network. Coordinating centre and site staff were paid from research grants from not-for-profit organizations. The network would not exist today without the dedication of these professionals. Thank you to all of our patient partners who shared their lived experiences and perspectives to ensure that the knowledge we co-create addresses the concerns of patients and the public. Creating the largest network of collaboration across Canadian emergency departments would not have been feasible without the tireless efforts of emergency department chiefs as well as research coordinators and research assistants at participating sites. Finally, our most humble and sincere gratitude to all of our colleagues in medicine, nursing, and the allied health professions who have been on the front lines of this pandemic from day 1 by staffing our ambulances, emergency departments, intensive care units, and hospitals and bravely facing the risks of COVID-19 to look after our fellow citizens and after one another. We dedicate this network to you.
Additional Information: The CCEDRRN governance structure includes patient partners on the Executive, Steering, Protocol Review and Publications, Data Access and Monitoring, Knowledge Translation, and Patient Engagement Committees. The Patient Engagement Committee with patient partners from across Canada with lived experience with COVID-19 provided input into study design and manuscript writing and provided advice on knowledge translation strategies.
J , Deeks
JJ , Berhane
et al; Cochrane COVID-19 Diagnostic Test Accuracy Group. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev
. 2021;3:CD013705. doi:10.1002/14651858.CD013705PubMedGoogle ScholarCrossref
LM , Lauer
SA , Laeyendecker
O , Boon
D , Lessler
J . Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med
. 2020;173(4):262-267. doi:10.7326/M20-1495
S , Allen
AJ , Graziadio
et al. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR–based tests? a systematic review of individual participant data. BMC Med
. 2020;18(1):346. doi:10.1186/s12916-020-01810-8
TE , Garcia Beltran
WF , Bard
et al. Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. FASEB J
. 2020;34(10):13877-13884. doi:10.1096/fj.202001700RR
CM , Anahtar
MN , Chiosi
et al. Clinical, laboratory, and radiologic characteristics of patients with initial false-negative severe acute respiratory syndrome coronavirus 2 nucleic acid amplification test results. Open Forum Infect Dis
. 2020;8(1):ofaa559. doi:10.1093/ofid/ofaa559PubMedGoogle ScholarCrossref
JP , Wilson
M , Smielewska
et al. Specificity and positive predictive value of SARS-CoV-2 nucleic acid amplification testing in a low-prevalence setting. Clin Microbiol Infect
. 2021;27(3):469.e9-469.e15. doi:10.1016/j.cmi.2020.10.003
J , Leister-Tebbe
H , Gardner
et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med
. 2022;386(15):1397-1408. doi:10.1056/NEJMoa2118542PubMedCrossref
CM , Rosychuk
RJ , McRae
et al; Canadian COVID-19 Emergency Department Rapid Response Network investigators; Network of Canadian Emergency Researchers; Canadian Critical Care Trials Group. Development of the Canadian COVID-19 Emergency Department Rapid Response Network population-based registry: a methodology study. CMAJ Open
. 2022;9(1):E261-E270. doi:10.9778/cmajo.20200290PubMedCrossref
CM , Rosychuk
RJ , Hau
et al; Canadian COVID-19 Rapid Response Network (CCEDRRN) investigators for the Network of Canadian Emergency Researchers, for the Canadian Critical Care Trials Group. Treatments, resource utilization, and outcomes of COVID-19 patients presenting to emergency departments across pandemic waves: an observational study by the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN). CJEM
. 2022;24(4):397-407. doi:10.1007/s43678-022-00275-3PubMedGoogle ScholarCrossref
AD , Hohl
CM , Rosychuk
et al; Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) investigators for the Network of Canadian Emergency Researchers and the Canadian Critical Care Trials Group. CCEDRRN COVID-19 Infection Score (CCIS): development and validation in a Canadian cohort of a clinical risk score to predict SARS-CoV-2 infection in patients presenting to the emergency department with suspected COVID-19. BMJ Open
. 2021;11(12):e055832. doi:10.1136/bmjopen-2021-055832
CM , Rosychuk
RJ , Archambault
et al; Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN) investigators for the Network of Canadian Emergency Researchers and the Canadian Critical Care Trials Group. The CCEDRRN COVID-19 Mortality Score to predict death among nonpalliative patients with COVID-19 presenting to emergency departments: a derivation and validation study. CMAJ Open
. 2022;10(1):E90-E99. doi:10.9778/cmajo.20210243
CM , Bourassa
L , Mathias
PC , Greninger
AL . Estimating the false-positive rate of highly automated SARS-CoV-2 nucleic acid amplification testing. J Clin Microbiol
. 2021;59(8):e0108021. doi:10.1128/JCM.01080-21
M , Górska
A , Mazzaferri
et al. Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis. Clin Microbiol Infect
. 2021;27(3):341-351. doi:10.1016/j.cmi.2020.11.002
CM , Rosychuk
RJ , Hau
et al. Treatments, resource utilization, and outcomes of COVID-19 patients presenting to emergency departments across pandemic waves: an observational study by the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN). medRxiv
. Preprint posted online August 1, 2021. doi:10.1101/2021.07.30.21261288
RA , Herigon
JC , Benedetti
A , Pollock
NR , Denkinger
CM . Performance of saliva, oropharyngeal swabs, and nasal swabs for SARS-CoV-2 molecular detection: a systematic review and meta-analysis. J Clin Microbiol
. 2021;59(5):e02881-20. doi:10.1128/JCM.02881-20
G , Lawandi
A , Schiller
et al. Comparison of saliva and nasopharyngeal swab nucleic acid amplification testing for detection of SARS-CoV-2: a systematic review and meta-analysis. JAMA Intern Med
. 2021;181(3):353-360. doi:10.1001/jamainternmed.2020.8876
GD , Schwartz
L , Hymel
P , Fielding
J . False positive results with SARS-CoV-2 RT-PCR tests and how to evaluate a RT-PCR–positive test for the possibility of a false positive result. J Occup Environ Med
. 2021;63(3):e159-e162. doi:10.1097/JOM.0000000000002138